BioMarin Pharmaceutical (BMRN)
(Delayed Data from NSDQ)
$82.13 USD
+1.22 (1.51%)
Updated Apr 29, 2024 04:00 PM ET
After-Market: $82.29 +0.16 (0.19%) 7:58 PM ET
2-Buy of 5 2
C Value D Growth A Momentum C VGM
Fundamental Charts
About Cash from Investing (Quarterly)
The company's quarterly Cash from Investing value is the sum of the company's current quarter cash position resulting from any gains or losses from investments in the financial markets, operating activities, and changes resulting from amounts spent on investments in capital assets such as plant and equipment. When evaluating the Cash from Investing value, it is important to consider each of the various activities which contribute to the overall change in cash position. A company can have a negative cash flow from investing and have a positive cash from Cash from operations or financing.
BMRN 82.13 +1.22(1.51%)
Will BMRN be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for BMRN based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for BMRN
BioMarin (BMRN) Beats on Q1 Earnings, Voxzogo Drives Sales
BioMarin (BMRN) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
BMRN: What are Zacks experts saying now?
Zacks Private Portfolio Services
BioMarin Pharmaceutical (BMRN) Tops Q1 Earnings Estimates
Is a Surprise Coming for BioMarin (BMRN) This Earnings Season?
AstraZeneca (AZN) to Report Q1 Earnings: Here's What to Expect
Other News for BMRN
Biotech Sector: M&A Fuels Renewed Excitement
Analysts Offer Insights on Healthcare Companies: Edwards Lifesciences (EW), BioMarin Pharmaceutical (BMRN) and Hookipa Pharma (HOOK)
Buy Rating Affirmed for BioMarin Pharmaceutical Amidst Strong Earnings and Voxzogo’s Growth Potential
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
Biotech Alert: Searches spiking for these stocks today